Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the side effects of sirolimus (rapamycin) given in
combination with chemotherapy (Mitoxantrone + Etoposide + Cytarabine (MEC)) on high risk
myeloid leukemias.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania